IE63-specific T-cell responses associate with control of subclinical varicella zoster virus reactivation in individuals with malignancies

British Journal of Cancer

Volumn 102, Issue 4, 2010, Pages 727-730

  Malavige, G N ^a,b   Rohanachandra, L T ^a   Jones, L ^b   Crack, L ^b   Perera, M ^c   Fernando, N ^a   Guruge, D ^a   Ogg, G S ^b,d  

^a UNIVERSITY OF SRI JAYEWARDENEPURA   (Sri Lanka)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c National Cancer Institute   (Sri Lanka)

^d CHURCHILL HOSPITAL   (United Kingdom)

Author keywords

IE63; Malignancy; T cell responses; Varicella zoster virus

Indexed keywords

ANTINEOPLASTIC AGENT; GAMMA INTERFERON; IMMEDIATE EARLY PROTEIN 63; UNCLASSIFIED DRUG; VARICELLA ZOSTER VACCINE; VIRUS GLYCOPROTEIN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER PATIENT; CELLULAR IMMUNITY; COLON CANCER; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; EX VIVO STUDY; FEMALE; HEMATOLOGIC MALIGNANCY; HERPES ZOSTER; HUMAN; IMMUNE DEFICIENCY; LEUKOCYTE COUNT; LUNG CANCER; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OSTEOSARCOMA; OVARY CANCER; PRIORITY JOURNAL; RECTUM CANCER; SOLID TUMOR; T LYMPHOCYTE ACTIVATION; UTERINE CERVIX CANCER; UTERUS CANCER; VARICELLA ZOSTER VIRUS; VIREMIA; VIRUS IMMUNITY; VIRUS REACTIVATION;

ADULT; AGED; FEMALE; HERPESVIRUS 3, HUMAN; HUMANS; IMMEDIATE-EARLY PROTEINS; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; NEOPLASMS; T-LYMPHOCYTES; VIRAL ENVELOPE PROTEINS; VIRAL VACCINES; VIREMIA; VIRUS ACTIVATION;

EID: 76949084972     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6605542     Document Type: Article

References (24)

1. Arvin AM, Pollard RB, Rasmussen LE, Merigan TC (1978) Selective impairment of lymphocyte reactivity to varicella-zoster virus antigen among untreated patients with lymphoma. J Infect Dis 137: 531-540
2. Arvin AM, Pollard RB, Rasmussen LE, Merigan TC (1980) Cellular and humoral immunity in the pathogenesis of recurrent herpes viral infections in patients with lymphoma. J Clin Invest 65: 869-878
3. Currier JR, Kuta EG, Turk E, Earhart LB, Loomis-Price L, Janetzki S, Ferrari G, Birx DL, Cox JH (2002) A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods 260: 157-172
4. Gallagher JG, Merigan TC (1979) Prolonged herpes-zoster infection associated with immunosuppressive therapy. Ann Intern Med 91: 842-846
5. Graue N, Grabbe S, Dissemond J (2006) [Disseminated herpes zoster in diabetes mellitus]. Dtsch Med Wochenschr 131: 384-386
6. Hackanson B, Zeiser R, Bley TA, Pantazis G, Huzly D, Bertz H, Finke J (2005) Fatal varicella zoster virus encephalitis in two patients following allogeneic hematopoietic stem cell transplantation. Clin Transplant 19: 566-570
7. Jones L, Black AP, Malavige GN, Ogg GS (2006) Persistent high frequencies of varicella-zoster virus ORF4 protein-specific CD4+ T cells after primary infection. J Virol 80: 9772-9778
8. Jones L, Black AP, Malavige GN, Ogg GS (2007) Phenotypic analysis of human CD4+ T cells specific for immediate early protein IE63 of varicella zoster virus. Eur J Immunol 37: 3393-3403
9. Kiewe P, Wojtke S, Thiel E, Nagorsen D (2009) Antiviral cellular immunity in colorectal cancer patients. Hum Immunol 70: 85-88
10. Levin MJ, Smith JG, Kaufhold RM, Barber D, Hayward AR, Chan CY, Chan IS, Li DJ, Wang W, Keller PM, Shaw A, Silber JL, Schlienger K, Chalikonda I, Vessey SJ, Caulfield MJ (2003) Decline in varicella-zoster virus (VZV)-specific cell-mediated immunity with increasing age and boosting with a high-hose VZV vaccine. J Infect Dis 188: 1336-1344
11. Malavige GN, Jones L, Black AP, Ogg GS (2007) Rapid effector function of varicella-zoster virus glycoprotein I-specific CD4+ T cells many decades after primary infection. J Infect Dis 195: 660-664
12. Malavige GN, Jones L, Black AP, Ogg GS (2008a) Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clin Exp Immunol 152: 522-531
13. Malavige GN, Jones L, Kamaladasa SD, Wijewickrama A, Seneviratne SL, Black AP, Ogg GS (2008b) Viral load, clinical disease severity and cellular immune responses in primary varicella zoster virus infection in Sri Lanka. PLoS ONE 3: e3789
14. Miller AE (1980) Selective decline in cellular immune response to varicella-zoster in the elderly. Neurology 30: 582-587
15. Onunu AN, Uhunmwangho A (2004) Clinical spectrum of herpes zoster in HIV-infected versus non-HIV infected patients in Benin City, Nigeria. West Afr J Med 23: 300-304
16. Park HB, Kim KC, Park JH, Kang TY, Lee HS, Kim TH, Jun JB, Bae SC, Yoo DH, Craft J, Jung S (2004) Association of reduced CD4 T cell responses specific to varicella zoster virus with high incidence of herpes zoster in patients with systemic lupus erythematosus. J Rheumatol 31: 2151-2155
17. Pevenstein SR, Williams RK, McChesney D, Mont EK, Smialek JE, Straus SE (1999) Quantitation of latent varicella-zoster virus and herpes simplex virus genomes in human trigeminal ganglia. J Virol 73: 10514-10518
18. Quinlivan ML, Ayres K, Ran H, McElwaine S, Leedham-Green M, Scott FT, Johnson RW, Breuer J (2007) Effect of viral load on the outcome of herpes zoster. J Clin Microbiol 45: 3909-3914
19. Schmader K (2001) Herpes zoster in older adults. Clin Infect Dis 32: 1481-1486
20. Schunemann S, Mainka C, Wolff MH (1998) Subclinical reactivation of varicella-zoster virus in immunocompromised and immunocompetent individuals. Intervirology 41: 98-102
21. Smith JG, Liu X, Kaufhold RM, Clair J, Caulfield MJ (2001) Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin Diagn Lab Immunol 8: 871-879
22. Sorensen HT, Olsen JH, Jepsen P, Johnsen SP, Schonheyder HC, Mellemkjaer L (2004) The risk and prognosis of cancer after hospitalisation for herpes zoster: a population-based follow-up study. Br J Cancer 91: 1275-1279
23. Wade JC (2006) Viral infections in patients with hematological malignancies. Hematology Am Soc Hemat Educ Program, 368-374
24. Whiteside TL (2006) Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16: 3-15